1.42%
5.37%
9.81%
24.22%
23.31%
41.16%
51.41%
AI Spotlight on GILD
Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.Gilead Sciences, Inc.has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc.
The company was incorporated in 1987 and is headquartered in Foster City, California.
Market Data
| Last Price | 96.95 |
| Change Percentage | 1.42% |
| Open | 96.56 |
| Previous Close | 95.59 |
| Market Cap ( Millions) | 120826 |
| Volume | 4858105 |
| Year High | 98.9 |
| Year Low | 62.07 |
| M A 50 | 91.85 |
| M A 200 | 79.38 |
Financial Ratios
| FCF Yield | 7.81% |
| Dividend Yield | 3.18% |
| ROE | 0.65% |
| Debt / Equity | 125.85% |
| Net Debt / EBIDTA | 464.71% |
| Price To Book | 6.54 |
| Price Earnings Ratio | 959.5 |
| Price To FCF | 12.81 |
| Price To sales | 4.27 |
| EV / EBITDA | 35.48 |
News
- Jan -30 - Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
- Jan -29 - Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
- Jan -25 - 5 Best CEFs This Month For Nearly 10% Yield (January 2025)
- Jan -23 - GILD vs. ALNY: Which Stock Is the Better Value Option?
- Jan -21 - Why Gilead Sciences (GILD) Outpaced the Stock Market Today
- Jan -20 - Can Gilead Sciences Sustain Its Growth Momentum in 2025?
- Jan -17 - The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences
- Jan -15 - Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- Jan -15 - Gilead Sciences, US government settle patent case over HIV prevention drugs
- Jan -13 - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
- Jan -13 - Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)
- Jan -13 - Gilead CEO on funding for new HIV prevention medicine
- Jan -13 - Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
- Jan -13 - Compugen initiated with bullish view at Oppenheimer, here's why
- Jan -11 - Gilead, LEO Pharma partner to develop programs for inflammatory diseases
- Jan -11 - Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
- Jan -09 - Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
- Jan -07 - Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA
- Jan -04 - Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
- Jan -03 - Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Medicines
Expected Growth : 2.0 %
What the company do ?
Innovative Medicines from Gilead Sciences, Inc. develops and commercializes novel therapeutics for life-threatening diseases, including HIV, liver diseases, and oncology.
Why we expect these perspectives ?
Gilead Sciences' Innovative Medicines segment growth is driven by increasing demand for HIV treatments, such as Biktarvy and Descovy, as well as the company's expanding oncology portfolio, including Yescarta and Tecartus. Additionally, the company's strategic investments in research and development, as well as its partnerships and collaborations, contribute to its growth.
Gilead Sciences, Inc. Products
| Product Range | What is it ? |
|---|---|
| HIV Products | Gilead Sciences, Inc. offers a range of HIV products, including Biktarvy, Descovy, Genvoya, Odefsey, Stribild, and Truvada, which are used to treat HIV infection. |
| Hepatitis B & C Products | Gilead Sciences, Inc. offers products such as Vemlidy, Viread, and Harvoni, which are used to treat chronic hepatitis B and C. |
| Cell Therapy | Gilead Sciences, Inc. offers Yescarta, a chimeric antigen receptor T cell (CAR-T) therapy, which is used to treat certain types of non-Hodgkin lymphoma. |
| Inflammation Products | Gilead Sciences, Inc. offers filgotinib, a JAK inhibitor, which is used to treat moderate to severe rheumatoid arthritis. |
| Oncology Products | Gilead Sciences, Inc. offers Zydelig, a PI3K delta inhibitor, which is used to treat certain types of blood cancers. |
Gilead Sciences, Inc.'s Porter Forces
Threat Of Substitutes
Gilead Sciences, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for diseases such as HIV, hepatitis, and cancer. However, the company's strong brand recognition and patented products mitigate this threat to some extent.
Bargaining Power Of Customers
Gilead Sciences, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the complexity of the pharmaceutical supply chain. The company's products are often reimbursed by payers, reducing the bargaining power of customers.
Bargaining Power Of Suppliers
Gilead Sciences, Inc. has a low bargaining power of suppliers due to the company's significant scale and global presence. The company has a diversified supplier base, which reduces its dependence on individual suppliers.
Threat Of New Entrants
Gilead Sciences, Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including significant R&D investments, regulatory hurdles, and patent protections.
Intensity Of Rivalry
Gilead Sciences, Inc. operates in a highly competitive pharmaceutical industry, with intense rivalry among established players. The company faces competition from other major pharmaceutical companies, as well as emerging biotech firms.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 52.34% |
| Debt Cost | 4.62% |
| Equity Weight | 47.66% |
| Equity Cost | 5.12% |
| WACC | 4.86% |
| Leverage | 109.84% |
Gilead Sciences, Inc. : Quality Control
Gilead Sciences, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LLY | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, … |
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Gilead Sciences
A-Score
1-Year Total Return ->
🥉
Merck
A-Score
1-Year Total Return ->
4
J&J
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
